Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Mexico for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Mexico only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Mexico (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jeffrey Neidhart (NPI 1801972518)

Field	Value
Entity Type	Individual
Organization	Jeffrey Neidhart
Address	2325 E 30th St
City	Farmington
State	NM
ZIP	87401
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	October 27, 2006

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

This provider’s billing footprint is effectively single‑payer Medicare: lifetime Medicare revenue is $1.4M and there is no Medicaid billing on file, indicating no recorded Medicaid participation in the dataset. That concentration means payer risk is concentrated in Medicare reimbursement patterns rather than a diversified public-payer mix.

Revenue is highly concentrated in three codes: the precomputed top‑3 Medicare codes account for 76.9% of the provider’s Medicare revenue, driven by J9271 ($593.4K, 43.1%), J0897 ($358.6K, 26.1%), and 99215 ($105.9K, 7.7%). This concentration shows that a small set of high-cost drug administrations and high‑complexity office visits dominate the financial profile.

The code mix points to an outpatient oncology infusion and management practice model: large revenue shares from J9271 (pembrolizumab) and J0897 (denosumab) together with chemotherapy administration codes such as 96413 and infusion/add‑on codes (96365, 96367, 96417) indicate regular in‑office systemic cancer therapy and supportive bone‑health treatments. Frequent use of E&M codes 99215 and 99214 alongside infusion codes suggests combined infusion visits with high medical decision making and ongoing complex disease management.

Competitively, the provider appears specialized on denosumab administration: J0897 generates $358.6K (26.1% of Medicare revenue) and ranks #293 of 10057 nationally (97th percentile), described in the source as "notably above typical national volume for this code," which signals above‑typical scale for bone‑modifying therapy relative to peers. This could reflect a referral pipeline for metastatic bone disease or a practice emphasis on bone health in oncology patients.

By contrast, pembrolizumab (J9271) contributes $593.4K (43.1%) but ranks #771 of 1841 nationally (57th percentile), characterized as a typical volume for that drug; this implies the provider administers significant amounts of immunotherapy but is not a dominant national outlier for pembrolizumab. The juxtaposition—high absolute revenue from J9271 but only typical comparative volume—suggests local demand or pricing contributes materially to revenue without exceptional national standing for that code.

The provider is an extreme outlier on high‑complexity office visits: 99215 accounts for $105.9K (7.7% of Medicare revenue) and ranks #529 of 145531 providers nationally (100th percentile), labeled an "extreme outlier, far above typical national volume for this code." This pattern is consistent with managing a caseload of medically complex established oncology patients and billing many high‑acuity evaluation & management visits.

Ancillary services and monitoring are present at scale: frequent lab and monitoring codes appear in the top 25 (for example, 85025 CBC at 1.4K claims and 80053 CMP at 941 claims, both with high national percentiles), supporting the conclusion that the clinic provides on‑site laboratory monitoring and routine cancer surveillance. These downstream services align with in‑office infusion workflows and reinforce the integrated outpatient oncology care model suggested by the drug and infusion codes.

The provider has long tenure in the Medicare program—NPI enumerated on 2006-10-27 (~20 years ago)—which indicates an established practice presence that may support steady referral relationships and sustained Medicare billing patterns over time. Combined with the revenue concentration and code mix, the longevity suggests an entrenched outpatient oncology operation centered on infusions, bone‑targeted therapy, and high‑complexity medical management.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

45 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	13,800	$40	$593.4K
J0897	Injection, denosumab, 1 mg	19,920	$20	$358.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	800	$130	$105.9K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	7,880	$10	$47.3K
J1439	Injection, ferric carboxymaltose, 1 mg	45,750	$1	$45.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	420	$90	$37.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	370	$100	$35.3K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	170	$130	$23.3K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	120	$170	$19.5K
36415	In this procedure, the provider inserts a needle into a vein to collect a blood sample.	1,450	$10	$11.6K

Showing 1–10 of 45

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Mexico Distribution

Jeffrey Neidhart — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Mexico

Full comparison — all codes billed, vs. state median

45 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	10	9,400	$40	$469.6K
J0897	3	50	3,150	$20	$113.2K
J0885	1	10	7,080	$10	$35.8K
J9217	13	20	180	$130	$23.4K
J1439	1	10	25,500	$1	$23.1K
96413	4	40	170	$90	$17.7K
J3490	8	20	40	$150	$16.7K
84443	29	60	110	$20	$13.3K
99214	245	2,700	90	$70	$12.9K
80053	8	90	100	$10	$11.5K

Showing 1–10 of 45

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jeffrey Neidhart, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
San Juan Oncology Associates, PC	NM	Hematology & Oncology Physician	$0	$1.9M
Brian Ulrich	TX	Medical Oncology Physician	$1.2M	$0
Sardar Imam	NM	Hematology & Oncology Physician	$538.8K	$0
Ankit Anand	NV	Hematology & Oncology Physician	$315.5K	$0

Nearby Providers

Other providers in the same ZIP code as Jeffrey Neidhart, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
San Juan Regional Medical Center, Inc.	NM	General Acute Care Hospital	$0	$141.5M
Basin Coordinated Healthcare,inc	NM	Personal Care Attendant	$0	$79.7M
Presbyterian Medical Services	NM	Federally Qualified Health Center (FQHC)	$0	$41.2M
Links Ii Inc	NM	In Home Supportive Care Agency	$0	$38.9M
Generations Personal Care, Inc	NM	Personal Care Attendant	$0	$33.9M
Southwestern Private Services, Inc.	NM	Home Health Agency	$0	$30.4M
San Juan Regional Medical Center Inc	NM	Emergency Medicine Physician	$0	$23.8M
San Juan Center For Independence	NM	Home Health Agency	$0	$22.5M
Cottonwood Clinical Services, Inc.	NM	Community/Behavioral Health Agency	$0	$18.1M
San Juan Regional Medical Center Inc	NM	Pediatrics Physician	$0	$15.7M

Jeffrey Neidhart — Billing Profile & Reimbursement Data

Sign up for Jeffrey Neidhart — Billing Profile & Reimbursement Data policy alerts

Jeffrey Neidhart — Billing Profile & Reimbursement Data

Sign up for Jeffrey Neidhart — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References